Réflexion intéréssante d'un chercheur sur les cas complexes

[un_ptit_gars]

Hello à tous,

Je vous partage ici les réflexions d'un chercheur sur les entremélements des différents systèmes dans les cas complexes tels que nous les connaissons. C'est un texte technique, pas forcément simple a lire pour les gens qui n'ont pas une longue route dans ces sphères la, mais qui amène a des réflexions très intéréssantes lors de sa conclusion (que je partage tout a fait).

Bonne lecture!

Pti gars

-----------------------------------------

Synthèse de "Mohammed Attallah" :

I have been working through an extraordinarily complex case involving Long COVID, severe ME/CFS physiology, hyperadrenergic POTS, MCAS-type hyperreactivity, recurrent SIBO and intestinal methanogen overgrowth, hydrogen sulfide-producing bacteria, substantial intestinal inflammation, mold and mycotoxin exposure, elevated toxic metals, impaired digestion, severe nutrient depletion, progressive muscle loss and profound mitochondrial respiratory-chain dysfunction. What makes this case important is not any single abnormal laboratory value. It is what happens when all of these findings are placed beside one another and interpreted as one biological system.
If someone looks only at the breath test, they see methane and think about killing methanogens. If they look only at the microbiome, they see dysbiosis and think about antimicrobials. If they look only at mold testing, they think about antifungals and binders. If they look only at MCAS, they think about histamine. If they look only at POTS, they think about heart rate and blood pressure. If they look only at environmental toxicants, they think about detoxification. But the human body does not operate as separate laboratory compartments. The mitochondria, intestinal epithelium, immune system, autonomic nervous system, vascular system, liver, bile acids, pancreatic enzymes, microbial ecosystem, nutrient status and environmental exposures are continuously interacting.
When I reconstructed this case mechanistically, what emerged was a host attempting to compensate for profound cellular energetic dysfunction while simultaneously dealing with immune activation, autonomic instability, impaired intestinal motility, mucosal inflammation, abnormal microbial metabolism, altered digestive physiology, toxicant exposure and progressive depletion of the nutritional resources required to maintain those systems.
The mitochondrial findings alone are striking. MitoSwab testing showed Complex IV activity at only 22% of the normal mean, with an absolute activity of 0.069. Complex II plus III activity was only 16% of the normal mean at 0.014. At exactly the same time, citrate synthase was 68.13, approximately 563% of the normal mean, while the Complex I to Complex IV ratio reached 51.0 compared with a reference range of 12.1 to 30.3.
Citrate synthase is commonly used as a marker of mitochondrial content. When it is elevated to approximately 563% of the normal mean while respiratory-chain activity remains profoundly impaired, I do not see a body that has simply stopped making mitochondria. I see a body attempting to compensate. The cells appear to recognize that their respiratory capacity is inadequate and are increasing mitochondrial mass in an effort to maintain energy production. But producing more mitochondria cannot completely solve the problem if the machinery inside those mitochondria remains functionally restricted.
Complex IV, cytochrome c oxidase, is the terminal enzyme of the mitochondrial electron-transport chain. Electrons ultimately reach Complex IV, where molecular oxygen acts as the final electron acceptor. Complexes I, III and IV contribute to generating the proton electrochemical gradient across the inner mitochondrial membrane, and ATP synthase uses that gradient to phosphorylate ADP into ATP. If terminal respiratory-chain activity becomes severely constrained, increasing mitochondrial quantity does not necessarily restore ATP production. The body can therefore be building more mitochondrial machinery while remaining trapped behind the same biochemical bottleneck.
That becomes even more interesting when the gastrointestinal microbiome is added to the picture. The microbiome showed enrichment of hydrogen sulfide-associated organisms. Desulfovibrio was approximately 0.944% and Bilophila wadsworthia approximately 0.408%, with the combined hydrogen sulfide-producing group reported around the 96th percentile in one analysis. Later analysis also reported Desulfovibrio at approximately 1.73 × 10⁹ CFU/g.
Hydrogen sulfide is not simply an intestinal gas responsible for odor. It is a biologically active signaling molecule, and at sufficiently high concentrations it can inhibit mitochondrial respiration. One of its important molecular targets is cytochrome c oxidase, Complex IV, where H2S can interact with the heme a3-CuB catalytic center responsible for reducing molecular oxygen. Excess inhibition at this site can slow electron transfer, impair proton pumping, reduce mitochondrial membrane potential and ultimately reduce oxidative ATP production.
Now place those findings beside one another. The host has an intestinal ecology enriched in organisms capable of producing hydrogen sulfide, while mitochondrial testing shows Complex IV operating at only 22% of the normal mean and Complex II plus III at only 16%. At the same time, citrate synthase is 563%, suggesting enormous attempted mitochondrial compensation. That is why I do not look at a microbiome report and simply ask which organism needs to be killed. I want to know what the organism metabolizes, what it produces, which host receptors or enzymes those metabolites interact with, which tissue compartments are exposed and whether the host already demonstrates dysfunction in the same biochemical pathway.
But there is an even more fundamental question: why did the microbial overgrowth develop in the first place? This patient has severe autonomic dysfunction. During NASA Lean testing, the supine heart rate was approximately 72 beats per minute. Upright positioning produced severe intolerance and collapse, with the heart rate subsequently reaching approximately 140 beats per minute. The records also describe severe orthostatic intolerance, post-exertional malaise, sensory hypersensitivity and profound autonomic instability.
The gastrointestinal tract is not simply a passive container for bacteria. It is an electrically active, neurologically regulated organ. Between meals, the stomach and small intestine generate the migrating motor complex. Phase III produces strong propagating contractions that sweep residual food, secretions, microorganisms and cellular debris distally through the gastrointestinal tract. If post-viral autonomic and enteric regulation becomes impaired, small-intestinal clearance can slow. Luminal residence time increases, microorganisms have more time to proliferate and ferment substrate, methanogens can expand and fermentation products increase. Those microbial products can then affect the mucosal immune system, epithelial cells, enteric nerves and the broader host.
The patient originally demonstrated hydrogen-predominant SIBO, with a hydrogen rise of approximately 65 ppm and a peak around 126 ppm. Later, the ecosystem shifted dramatically toward methane, reaching approximately 90.11 ppm. If I look only at the methane value, the obvious response is to kill methanogens. But if post-viral autonomic dysfunction, impaired migrating motor complex activity, altered digestion and abnormal intestinal ecology created the environment in which those organisms expanded, killing them does not necessarily remove the ecological conditions responsible for their expansion. You can suppress a population while leaving the niche intact and then be surprised when the same problem returns.
This patient actually received repeated antimicrobial strategies. Rifaximin 550 mg three times daily for 14 days was used more than once. Allicin was used. Oregano and goldenseal appeared in later regimens. Nystatin, itraconazole, monolaurin and multiple botanical antimicrobial preparations were added at different stages. There were also extensive interventions including ozone, Ten-Pass ozone, EBOO, methylene blue, high-dose vitamin C, phospholipid infusions, peptides and multiple additional compounds. The records describe transient gastrointestinal improvement after rifaximin followed by rapid recurrence rather than durable restoration of the ecosystem.
Now add the intestinal inflammatory data. Fecal calprotectin followed a trajectory that included approximately 25, 120, 80.9, 57, 202 and 122 mcg/g. Fecal lactoferrin became positive. Secretory IgA reached greater than 7,500 and later remained around 5,310 µg/g. These are not the findings of a quiet intestinal mucosa. They indicate substantial mucosal immune activity and, with calprotectin and lactoferrin, neutrophil-associated intestinal inflammation.
This matters because microbial killing is not biologically neutral. Gram-negative bacterial injury can increase host exposure to lipopolysaccharide and other microbial components, including lipoproteins, peptidoglycan fragments, nucleic acids and additional pathogen-associated molecular patterns. LPS can interact with LPS-binding protein, CD14 and the TLR4-MD2 receptor complex, activating MyD88- and TRIF-dependent pathways. These pathways can recruit IRAK proteins and TRAF6, converge on TAK1, activate the IKK complex, promote IκB degradation and allow NF-kappaB to enter the nucleus and alter inflammatory transcription.
Now imagine generating additional microbial antigen exposure inside a host whose inflammatory system is already highly activated. The Long Hauler Index was 19.43 compared with a reference below 0.70. IFN-gamma was approximately 183.2 pg/mL, IL-4 was 61.2 pg/mL, IL-13 was 53.3 pg/mL, IL-6 was 32.8 pg/mL, IL-8 was 26.4 pg/mL, IL-10 was 13.9 pg/mL and TNF-alpha was 12.1 pg/mL. Intermediate CD14+CD16+ monocytes were elevated at approximately 14.27%.
This is why I believe the condition of the host has to determine therapeutic sequencing. The relevant question is not merely whether a compound can reduce an organism. The relevant question is what happens when that intervention is introduced into a person who simultaneously has major cytokine activation, intestinal inflammation, MCAS-type hyperreactivity, autonomic instability, mitochondrial respiratory-chain impairment and declining nutritional reserve.
The intestinal ecology itself is also remarkable. At one stage Bacteroidetes reached approximately 73% and Bacteroides approximately 64.67%, while Bifidobacterium was approximately 0.02%, Roseburia approximately 0.07% and Coprococcus approximately 0.01%. Faecalibacterium remained relatively preserved at approximately 10.42%, but much of the functional redundancy around it had disappeared. The analysis also reported Gram-negative abundance around 79.54%, approximately the 99th percentile. At the same time, the patient's diet became extraordinarily restricted. At one point it consisted largely of only two or three puréed foods in very small quantities, including zucchini, squash or chayote, along with defatted chicken broth.
That is ecologically important. Bifidobacteria depend heavily on fermentable carbohydrate substrates and participate in cross-feeding networks that produce acetate and lactate, which can then support other organisms involved in butyrate production. Roseburia, Coprococcus and other butyrate-associated organisms contribute to the metabolic redundancy necessary for stable short-chain-fatty-acid production. The reports describe a system where Bifidobacterium had fallen to approximately 0.02%, Roseburia to 0.07%, Eubacterium to 0.09% and Coprococcus to 0.01%, leaving Faecalibacterium relatively preserved but surrounded by a collapsing cross-feeding network.
At the same time, Bacteroides became dominant. Bacteroides species possess extensive polysaccharide-utilization loci that allow them to metabolize a broad spectrum of carbohydrates. When microbiota-accessible carbohydrates become severely restricted, some members of this ecological group can increasingly utilize host-derived mucosal glycans. That raises a fundamentally different question: what happens when repeated antimicrobial pressure and extreme food restriction remove microbial competitors and dietary substrate at the same time that the intestinal mucus layer is already inflamed?
This is why I do not think of dysbiosis as a list of good bacteria and bad bacteria. I think about substrate availability, microbial cross-feeding, mucus utilization, bile acids, intestinal pH, transit time, oxygen availability, electron acceptors, immune pressure and epithelial metabolism. An organism expands because an ecological niche permits it to expand. If that niche is not corrected, killing the organism may simply clear the space for the same ecology to reappear.
Bile acids and pancreatic function added another layer. Stool analysis showed conjugated bile acids including TCDCA around 1,040 ng/g and TCA around 1,020 ng/g, while pancreatic elastase later reached approximately 160 µg/g. Bile acids are not simply detergents that allow dietary fat to be absorbed. They are signaling molecules that interact with receptors such as FXR and TGR5 and influence intestinal motility, hepatic bile-acid synthesis, metabolic regulation, immune signaling and microbial ecology. Pancreatic digestion also determines which proteins, fats and carbohydrates arrive intact in downstream regions of the intestine and therefore which organisms are metabolically favored.
The entire system therefore begins feeding back on itself. Autonomic dysfunction alters motility, altered motility increases microbial residence time, impaired digestion changes substrate delivery, bile acids change microbial selection, microorganisms generate hydrogen, methane, hydrogen sulfide and other metabolites, those metabolites influence the epithelium, immune system and nervous system, and mucosal inflammation changes the environment again.
There is also a major vascular component in this case. The reports document Stage 3.5 out of 4 widespread amyloid fibrin microclots and endothelial casts. They also report PAI-1 4G/4G, Protein S activity around 54%, fibrinogen around 436 mg/dL, anticardiolipin IgM increasing to 27 MPL U/mL and phosphatidylserine/prothrombin antibodies.
Regardless of how one ultimately interprets every component of that testing, the mechanistic concern being raised is perfusion. A cell can have completely normal arterial oxygen saturation while still struggling if microvascular delivery of oxygen and substrate is impaired. Mitochondria do not merely require oxygen to exist in the bloodstream; they require oxygen to reach the tissue. That creates another possible collision: impaired mitochondrial respiratory machinery on one side and impaired microvascular substrate delivery on the other. A cell already operating with Complex IV at 22% has even less room to tolerate compromised tissue perfusion.
Then I looked at the environmental toxicant profile. Urinary testing showed barium at 7.43 µg/g compared with the laboratory reference of 5.59 or lower, palladium at 1.42 µg/g compared with 0.20 or lower, thallium at 1.13 µg/g compared with 0.43 or lower, and uranium at 1.24 µg/g compared with 0.04 or lower. The uranium value was approximately 31 times the laboratory upper reference limit.
These metals are not interchangeable, and simply calling them heavy metals hides their individual chemistry. Barium has a particularly important relationship with potassium-channel physiology. Ba²⁺ can enter potassium-channel pores from the extracellular side and interfere with potassium conductance. Potassium efflux is fundamental to membrane repolarization. Membrane repolarization is necessary for repetitive electrical activity in neurons, cardiac tissue and smooth muscle. In intestinal smooth muscle, potassium and calcium conductances are central to coordinated contraction and relaxation. If potassium-channel activity is disturbed, the electrical behavior of the cell changes and therefore motility can change as well.
Thallium behaves differently. Tl+ has ionic properties sufficiently similar to potassium that it can exploit biological systems normally designed to handle K+. The supplied analysis describes thallium entering cells through potassium-handling machinery and interacting with sulfhydryl-dependent mitochondrial proteins, including succinate dehydrogenase, Complex II. The mechanistic concern therefore again converges on mitochondrial energetics, redox stress, ion homeostasis and membrane potential.
Uranium introduces another type of chemistry. In its uranyl form, UO2²⁺ has strong affinity for oxygen-containing ligands, particularly phosphate and carbonate groups. The supplied analysis describes uranyl interaction with phosphate-rich structures, including phospholipid phosphate head groups. Cell membranes are not passive walls. They contain receptors, ion channels, ATPases, transport proteins and the electrochemical machinery that separates the intracellular environment from the outside world. Interference with membrane phospholipids can therefore influence membrane fluidity, ion transport and membrane-associated enzyme activity.
Now consider how these toxicants are supposed to leave the body. The word detox is often used as though elimination happens automatically once a binder or supplement is introduced. But biological clearance requires functioning physiology. Cells have to maintain membrane gradients, conjugate compounds, transport metabolites, package substances into bile, perform renal tubular transport and actively export xenobiotics.
Many important export proteins belong to the ATP-binding cassette transporter family. P-glycoprotein, MRP2 and BCRP are examples of transporters that depend on ATP hydrolysis to undergo the conformational changes necessary for moving substrates across membranes. This brings us directly back to the mitochondrial findings. The same host being asked to clear environmental compounds has Complex IV activity at only 22% and Complex II plus III at 16%.
ATP is not simply the molecule responsible for whether someone feels energetic. ATP runs membrane pumps, maintains sodium and potassium gradients, powers active transport, supports protein synthesis, supports renal tubular transport, supports hepatic metabolism and is required for maintaining membrane architecture and cellular repair. So I cannot talk about detoxification in this person without talking about energy production. If mitochondrial ATP generation is profoundly constrained, then asking the body to perform more transport, more repair and more xenobiotic clearance creates an additional energetic demand on an already compromised system. That is what I mean when I talk about Host Capacity.
Then come the mycotoxins. Fumonisin B1 was 10.35 ng/g compared with a laboratory reference of 6.13 or lower. Satratoxin H was 0.62 ng/g compared with 0.18 or lower. Zearalenone was 1.79 ng/g compared with 0.67 or lower, and Aflatoxin B1 was 3.93 ng/g.
Again, these are different molecules with different molecular targets. Fumonisin B1 inhibits ceramide synthase, an enzyme involved in sphingolipid metabolism. Sphingolipids are critical structural components of cellular membranes, but they also function as signaling molecules regulating inflammation, apoptosis, stress responses and epithelial integrity. A toxin capable of interfering with sphingolipid synthesis therefore potentially intersects with membrane biology at exactly the same time the intestinal epithelium is already showing inflammatory injury.
Satratoxin H is a macrocyclic trichothecene. The supplied analysis describes interaction with the 60S ribosomal subunit and interference with protein translation, along with activation of the ribotoxic stress response. That matters enormously in the intestinal epithelium because these cells turn over rapidly. They continuously have to synthesize transporters, digestive enzymes, receptors, junctional proteins, cytoskeletal proteins and mucus-associated components. A tissue cannot repair itself without protein synthesis. Now place that beside calprotectin reaching 202 mcg/g and positive fecal lactoferrin. The mucosa is already being asked to repair itself under inflammatory stress.
Zearalenone introduces an endocrine mechanism. Zearalenone is structurally similar to 17-beta estradiol and can bind estrogen receptors ER-alpha and ER-beta. Once activated, these receptors influence transcriptional programs through estrogen-response elements and other co-regulatory pathways. The supplied analysis connects this signaling with intestinal epithelial gene expression, inflammatory signaling and tight-junction regulation.
This is why it is important not to incorrectly group every abnormal environmental marker together. Barium affects potassium-channel physiology, thallium behaves as a potassium mimetic and can interact with mitochondrial systems, uranium has strong phosphate and carbonate chemistry that can affect membrane structures, fumonisin interferes with sphingolipid synthesis, Satratoxin affects ribosomal function and zearalenone interacts with estrogen receptors. Different molecules have different molecular targets, but their downstream consequences begin converging on the same vulnerable systems: mitochondrial energy production, membrane integrity, ion gradients, epithelial repair, immune regulation and intestinal motility.
At the same time, the host is losing the nutritional capacity required to compensate for all of this. Vitamin D progressively fell from approximately 35 ng/mL to 13.6 and eventually 7.7 ng/mL. Intracellular micronutrient testing placed niacin or vitamin B3 around the deficiency threshold at 80%, with additional borderline findings involving copper, glutamine, oleic acid, serine and vitamin K2.
The vitamin D decline occurred alongside gastrointestinal symptoms suggestive of fat malassimilation, and the later coagulation profile showed PT 16.2 seconds, INR 1.3 and aPTT 35.4 seconds while thrombin time remained normal at 20.3 seconds. The supplied analysis raises impaired fat-soluble vitamin handling, including vitamin K physiology, as part of this pattern.
NAD biology is also relevant. Niacin is a precursor for NAD+, and NAD+ is required throughout cellular energy metabolism. Glycolysis requires NAD+. Pyruvate dehydrogenase requires NAD+. The TCA cycle contains multiple NAD-dependent dehydrogenases. Fatty-acid oxidation depends on NAD+/NADH redox cycling, and sirtuins also depend on NAD+. So the same host showing severe respiratory-chain impairment is also demonstrating weakness in one of the foundational micronutrient systems supporting redox metabolism.
Muscle reserve is disappearing as well. Serum creatinine moved into the approximately 0.52 to 0.58 mg/dL range, CK was below approximately 25 U/L in earlier testing, urinary 3-methylhistidine reached as high as approximately 575 µmol/g creatinine, and body weight fell from around 130 pounds to approximately 110 to 112 pounds. The records describe an extremely restricted diet and progressive skeletal-muscle wasting.
Skeletal muscle is not simply tissue used for movement. It is an enormous metabolic reservoir. During prolonged energetic or nutritional stress, muscle protein can be catabolized to release amino acids for gluconeogenesis, energy metabolism and essential protein synthesis. In that context, increasing 3-methylhistidine alongside falling body weight and low creatinine becomes part of a much larger picture of decreasing metabolic reserve.
Even the liver began showing evidence of increasing strain. ALT moved from approximately 26 U/L at baseline to 53 and eventually 61 U/L during a period involving oral itraconazole, concentrated herbal antimicrobial tinctures and extensive treatment exposure. The reports specifically describe this temporal progression while bilirubin and alkaline phosphatase remained normal.
This is where I believe both conventional medicine and integrative medicine need to become more sophisticated. There is an enormous difference between asking whether an antimicrobial can kill an organism and asking whether this particular host, at this particular stage of illness, has the mitochondrial reserve, hepatic reserve, mucosal integrity, nutrient availability, vascular delivery and autonomic stability required to tolerate the biological cost of that treatment. A treatment can have a valid mechanism against an organism and still be poorly sequenced for the person receiving it.
When I see methane at approximately 90 ppm, I do not stop at methanogens; I ask why intestinal motility failed. When I see Desulfovibrio and Bilophila, I do not stop at hydrogen sulfide; I ask what ecological conditions selected for those organisms, what substrates they are using, what bile-acid environment exists and whether their metabolites intersect with the mitochondrial abnormalities already present. When I see MCAS-type reactions, I do not stop at histamine; I ask what is lowering the mast-cell activation threshold. Is it cytokine signaling, autonomic instability, mucosal antigen exposure, environmental toxicants, mitochondrial stress or several of these simultaneously?
When I see mold and mycotoxins, I do not simply ask which binder should be used. I ask what each molecule actually does to ceramide synthesis, ribosomes, membranes, receptors, mitochondria and epithelial repair. When I see environmental metals, I do not simply say detox. I ask whether they interact with potassium channels, membrane phosphates, sulfhydryl groups, mitochondrial enzymes or renal physiology, and then I ask the question that has to come before aggressive clearance: does this host have enough ATP to perform the transport and repair being demanded of it? When I see dysbiosis, I do not immediately ask what should be killed. I ask what ecological pressure selected for the dysbiosis.
That means looking at Long COVID, autonomic dysfunction, the migrating motor complex, POTS, MCAS-type hyperreactivity, microvascular perfusion, intestinal inflammation, bile acids, pancreatic digestion, microbial cross-feeding, hydrogen, methane, hydrogen sulfide, Complex IV, Complex II plus III, citrate synthase, NAD+, ATP, membrane physiology, environmental toxicants, mycotoxins, liver function, vitamin status, muscle reserve and treatment history as one interconnected biological network.
Look at the host as a whole. Complex IV is at 22%, Complex II plus III is at 16%, citrate synthase is at 563%, the Long Hauler Index is 19.43, IFN-gamma is 183.2 pg/mL, methane reaches 90.11 ppm, calprotectin reaches 202 mcg/g, fecal lactoferrin is positive, vitamin D reaches 7.7 ng/mL, uranium is 1.24 µg/g, thallium is 1.13 µg/g, barium is 7.43 µg/g, Satratoxin H is 0.62 ng/g, Fumonisin B1 is 10.35 ng/g and Zearalenone is 1.79 ng/g. There are widespread microclot findings, profound autonomic dysfunction, declining body weight, decreasing muscle reserve, severe food intolerance and evidence of increasing hepatic burden.
When that is the biological state of the person, perhaps our first question should not automatically be which antibiotic, antifungal, antimicrobial herb, binder or elimination diet comes next. Perhaps the first question should be what physiological capacity remains and what needs to be restored before we demand even more from the system.
Not every deterioration after an intervention proves that the treatment is working. Not every severe reaction is die-off. Not every crash should automatically be called a Herxheimer reaction. Sometimes a fragile host may simply be experiencing another inflammatory, metabolic, hepatic or bioenergetic stress that it does not currently have the reserve to absorb.
That distinction matters enormously.
People living with Long COVID, ME/CFS, MCAS, POTS and complex gastrointestinal illness deserve more than having their biology divided into disconnected specialties and isolated laboratory abnormalities. The intestine communicates with the immune system, the immune system changes mitochondrial metabolism, the autonomic nervous system controls gastrointestinal motility and vascular tone, the microbiome generates metabolites capable of altering epithelial and mitochondrial physiology, mitochondria determine whether cells have enough ATP to maintain ion gradients, synthesize proteins, operate transporters and repair damaged membranes, environmental compounds can interfere with those same processes, and nutrition determines whether the biochemical raw materials needed for compensation are even available.
It is one system, and that is why the central principle of my work is Host Capacity. The organism matters, the methane matters, the hydrogen sulfide matters, the mold matters, the mycotoxins matter, the heavy metals matter and the inflammation matters, but none of those findings can be interpreted correctly without understanding the physiological condition of the host carrying them.
The most important question in a complex chronic illness case is often not, “What diagnosis does this abnormal marker belong to?” The deeper questions are what biological process this finding represents, what drove it, what it is doing downstream, which other abnormalities reinforce it, which compensatory systems are already working harder to maintain function, which systems are losing reserve and whether this person actually has enough physiological capacity to tolerate the intervention we are considering.
That is what I mean by looking mechanistically at the whole person rather than chasing isolated targets, and that is the question I believe conventional medicine, integrative medicine and anyone working with these complex patients must be willing to confront. If we repeatedly attack microbes, methane, mold, toxins and abnormal laboratory markers while ignoring mitochondrial respiratory capacity, ATP availability, mucosal injury, autonomic dysfunction, vascular delivery, nutrient depletion, membrane integrity, liver burden and ecological resilience, an intervention intended to help can become another stressor imposed on a biological system that is already struggling to compensate.
The question should never be only, “Can we kill the target?” The more important question is, can the host tolerate what we are about to do, and have we actually understood what created the problem in the first place?